Participation in orphan-drug development through additional acquisition of shares in ノーベルファーマ
First written in FY2019-Q1. 2 of 4 entries say "Restated". Latest entry: FY2021.
0 other companies' latest entry also says "Restated".
- FY2021RestatedAnnual report
「Our group invests in new drug development by pharmaceutical companies and others, earning a return on these investments once the drugs are launched (project finance), while prioritizing their sale and distribution to medical institutions (marketing).」
The company continues its business development strategy of combining investment in the development of drugs for rare diseases and other products with monetization through post-launch sales and distribution. - FY2019-Q3RestatedAnnual report
「Nobel Pharma Co., Ltd. has been included in the scope of equity-method accounting since the second-quarter consolidated accounting period because we acquired shares in the company.」
Following the acquisition of Nobel Pharma shares, the company continues to account for Nobel Pharma as an equity-method affiliate. - FY2019-Q2AdvancedAnnual report
「As shares in Nobelpharma Co., Ltd. were acquired, the company has been included in the scope of equity-method affiliates from the second quarter of the current consolidated fiscal year.」
Following the additional acquisition of Nobel Pharma shares, the company proceeded to include Nobel Pharma in the scope of equity-method accounting from 30 September 2018. - FY2019-Q1First statedAnnual report
「As part of this initiative, in May 2018 we acquired additional shares in Nobel Pharma Co., Ltd. (Chuo-ku, Tokyo), a company with strengths in developing drugs for rare diseases, increasing our stake to 20%.」
In May 2018, the company increased its stake in Nobel Pharma to 20%, expanding its involvement with a company specializing in the development of drugs for rare diseases.